Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Bausch + Lomb Corporation ( (BLCO) ).
On November 13, 2025, Bausch + Lomb Corporation announced its plans during an Investor Day event at the New York Stock Exchange, highlighting a transformation in its operations and a focus on sustainable growth. The company revealed a three-year plan targeting above-market revenue growth and margin expansion, driven by innovations in its eye health product pipeline. The event emphasized Bausch + Lomb’s commitment to leveraging AI and new technologies, with projected peak sales of pipeline products expected to reach approximately $7 billion. The company aims for a 5-7% revenue CAGR through 2028, with significant product launches anticipated across various segments, reaffirming its 2025 guidance and positioning itself for long-term value creation for shareholders.
The most recent analyst rating on (BLCO) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Bausch + Lomb Corporation stock, see the BLCO Stock Forecast page.
Spark’s Take on BLCO Stock
According to Spark, TipRanks’ AI Analyst, BLCO is a Neutral.
Bausch + Lomb Corporation’s overall stock score is driven by its strong technical momentum and positive earnings call outlook, which are offset by weak financial performance and valuation concerns. The company’s challenges in profitability and cash flow, along with a negative P/E ratio, weigh heavily on its score. However, the positive momentum and strategic management highlighted in the earnings call provide some optimism for future performance.
To see Spark’s full report on BLCO stock, click here.
More about Bausch + Lomb Corporation
Bausch + Lomb Corporation is a leading global eye health company dedicated to improving vision and eye health through a range of products including contact lenses, prescription products, over-the-counter options, and surgical devices. The company has a long-standing commitment to innovation and enhancing the standard of care in eye health.
Average Trading Volume: 517,659
Technical Sentiment Signal: Buy
Current Market Cap: $5.88B
See more insights into BLCO stock on TipRanks’ Stock Analysis page.